Cambrex and Tillotts Pharma Sign Agreement for Mesalamine-Based Technology

Cambrex (East Rutherford, NJ) says it has entered into a development and commercialization agreement with Tillotts Pharma (Rheinfelden, Switzerland), a subsidiary of Zeria Pharmaceutical (Tokyo), for a proprietary mesalamine-based (5-ASA) technology for use in the treatment of inflammatory bowel disease. The announcement “serves as a prime example of Cambrex's commitment to accelerating our customers' drug development processes by providing technology-added products and services and further underscores our goal to being a leading player in the development...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers